Correction: Ishikawa et al. Systematic Review of Beta-Lactam vs. Beta-Lactam plus Aminoglycoside Combination Therapy in Neutropenic Cancer Patients. Cancers 2024, 16, 1934

Text Correction

There was an error in the original publication. The authors wish to revise one sentence on Abstract, which was overlooked in the final proofreading.

A correction has been made to Abstract: Regarding treatment failure, combination therapy showed no significant differences compared with monotherapy (RR 0.99, 95% CI 0.94 to 1.03, moderate certainty of evidence).

Error in Table

In the original publication [1], there was a mistake in

Table 2. Summary of findings regarding the administration of beta-lactam compared to beta-lactam plus aminoglycoside for febrile neutropenia.

Beta-Lactam Compared to Beta-Lactam + Aminoglycoside for Febrile Neutropenia
Patient or population: febrile neutropenia; Intervention: beta-lactam; Comparison: beta-lactam + aminoglycoside
Outcomes	Anticipated absolute effects * (95% CI)		Relative effect (95% CI)	№ of participants (studies)	Certainty of the evidence (GRADE)	Comments
	Risk with beta-lactam + aminoglycoside	Risk with beta-lactam
All-cause mortality	81 per 1000	80 per 1000 (68 to 94)	OR 0.99 (0.84 to 1.16)	7023 (38 RCTs)	⨁⨁⨁⨁ High
Infection-related mortality	50 per 1000	42 per 1000 (33 to 53)	OR 0.83 (0.66 to 1.05)	6469 (34 RCTs)	⨁⨁⨁⨁ High
Treatment failure	420 per 1000	416 per 1000 (395 to 432)	OR 0.99 (0.94 to 1.03)	9285 (53 RCTs)	⨁⨁◯◯ Moderate a,b
Ag any dosing regimen	54 per 1000	25 per 1000 (19 to 32)	RR 0.46 (0.36 to 0.60)	6007 (28 RCTs)	⨁⨁⨁⨁ High

* The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; OR: odds ratio; RR: risk ratio; Ag: aminoglycoside; a. Differences decreased with low risk of bias regarding allocation concealment. b. Differences in effects between published and unpublished trials. GRADE Working Group grades of evidence. High certainty: we are very confident that the true effect lies close to the estimated effect. Moderate certainty: we are moderately confident in the estimated effect: the true effect is likely to be close to the estimated effect, but there is a possibility that it is substantially different. Low certainty: our confidence in the estimated effect is limited: the true effect may be substantially different from the estimated effect. Very low certainty: we have very little confidence in the estimated effect: the true effect is likely to be substantially different from the estimated effect.

as published. Table 2 should include relevant data on all-cause mortality, infection-related mortality, treatment mortality, and treatment failure. The corrected Table 2 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.